AR031638A1 - Composiciones farmaceuticas para potenciar la inmunogenicidad de antigenos poco inmunogenicos - Google Patents

Composiciones farmaceuticas para potenciar la inmunogenicidad de antigenos poco inmunogenicos

Info

Publication number
AR031638A1
AR031638A1 ARP010105662A ARP010105662A AR031638A1 AR 031638 A1 AR031638 A1 AR 031638A1 AR P010105662 A ARP010105662 A AR P010105662A AR P010105662 A ARP010105662 A AR P010105662A AR 031638 A1 AR031638 A1 AR 031638A1
Authority
AR
Argentina
Prior art keywords
compositions
vaccine
immunogenic
antigens
lysates
Prior art date
Application number
ARP010105662A
Other languages
English (en)
Inventor
Molina Luis Enrique Fernandez
Ramirez Belinda Sanchez
Pestana Eduardo Raul Suarez
La Barrera Aira Anabel De
Pardillo Circe Mesa
Leon Delgado Joel De
Rodriguez Yildian Diaz
Rodriguez Rolando Perez
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CU20000285A external-priority patent/CU23000A1/es
Priority claimed from CU20010167A external-priority patent/CU23009A1/es
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of AR031638A1 publication Critical patent/AR031638A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion ser relaciona con los medios para hacer inmunogénicos péptidos, polipéptidos, proteínas, sus correspondientes secuencias de ácidos nucleicos, células blanco de interés vacunal y sus lisados, sin hacer cambios estructurales en dichos antígenos, mediante su asociacion con proteoliposomas de muy pequena talla. El objeto de esta invencion es proporcionar composiciones inmunogénicas que contiene péptidos, polipéptidos, proteínas, sus correspondientes secuencias de ADN, células o sus lisados y proteoliposomas de muy pequena talla (VSSP), formados estos ultimos al unir el complejo de proteínas de la membrana externa (CPME) de Neisseria meningitidis con gangliosidos, mediante enlaces hidrofobos. Adicionalmente se describe como estas composiciones pueden formularse solas o formando emulsiones con el adyuvante incompleto de Freund (AIF) y también ser liofilizadas. La esencia de la invencion consiste en describir composiciones que permiten hacer inmunogénicos antígenos de muy baja inmunogenicidad, tales como receptores de factores de crecimiento, sin necesidad de recurrir a cambios estructurales en los mismos. En particular esta invencion muestra como preparar composiciones inmunoestimuladoras capaces de generar respuestas inmunes antígeno-específicas incluso en huéspedes inmunocomprometidos, como son o que padecen de cáncer e infecciones de origen viral o bacterianas cronicas. En estos pacientes, la administracion de las composiciones vacunales descritas, en esta invencion permite restaurar la funcionalidad de sectores de su sistema inmunitario. Las composiciones vacunales de esta invencion pueden ser utilizadas para proteger de o tratar enfermedades infecciosas malignas o autoinmunes.
ARP010105662A 2000-12-06 2001-12-05 Composiciones farmaceuticas para potenciar la inmunogenicidad de antigenos poco inmunogenicos AR031638A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20000285A CU23000A1 (es) 2000-12-06 2000-12-06 Composiciones vacunales para la inmunoterapia activa específica del cáncer
CU20010167A CU23009A1 (es) 2001-07-12 2001-07-12 Preparaciones para potenciar la inmunogenicidad depreparaciones para potenciar la inmunogenicidad de antígenos poco inmunogénicos antígenos poco inmunogénicos

Publications (1)

Publication Number Publication Date
AR031638A1 true AR031638A1 (es) 2003-09-24

Family

ID=38812545

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010105662A AR031638A1 (es) 2000-12-06 2001-12-05 Composiciones farmaceuticas para potenciar la inmunogenicidad de antigenos poco inmunogenicos

Country Status (19)

Country Link
US (1) US7776342B2 (es)
EP (1) EP1356822B1 (es)
JP (1) JP4210519B2 (es)
KR (1) KR100850473B1 (es)
CN (1) CN1291755C (es)
AR (1) AR031638A1 (es)
AT (1) ATE485833T1 (es)
AU (2) AU2151902A (es)
BR (1) BRPI0116013B8 (es)
CA (1) CA2431188C (es)
DE (1) DE60143363D1 (es)
DK (1) DK1356822T3 (es)
EA (1) EA005138B1 (es)
MX (1) MXPA03005032A (es)
NZ (1) NZ526282A (es)
PE (1) PE20020572A1 (es)
UY (1) UY27059A1 (es)
WO (1) WO2002045746A2 (es)
ZA (1) ZA200304411B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1358910A1 (de) * 2002-05-02 2003-11-05 B.R.A.H.M.S Aktiengesellschaft Verfahren und Mittel zur Prävention, Hemmung und Therapie von Krebserkrankungen
EP1367395A1 (de) * 2002-05-02 2003-12-03 B.R.A.H.M.S Aktiengesellschaft Diagnose von Neoplasmen mit Hilfe von anti-Gangliosid-Antikörpern
CU23257A1 (es) * 2003-02-27 2008-01-24 Centro Inmunologia Molecular COMPOSICIONES VACUNALES A BASE DE GANGLIOSIDOS PARA LA ADMINISTRACION SUBCUTáNEA
AR045815A1 (es) * 2003-10-09 2005-11-16 Ct Ingenieria Genetica Biotech Composiciones farmaceuticas que contienen antigenos del virus de papiloma humano
US8147840B2 (en) * 2004-05-14 2012-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human immunodeficiency virus (HIV) immunization strategies employing conformationally-stabilized, surface-occluded peptides comprising a gp41 2F5 epitope in association with lipid
US20110189231A1 (en) * 2008-06-17 2011-08-04 Denis Leclerc Compositions Comprising Salmonella Porins and Uses Thereof as Adjuvants and Vaccines
DK2654785T3 (da) * 2010-12-22 2019-06-24 Bayer Ip Gmbh Forøget immunrespons hos kvægracer
KR101323845B1 (ko) * 2011-01-21 2013-10-31 광주과학기술원 외막소포체를 유효성분으로 포함하는 항암용 약제학적 조성물
CU24070B1 (es) * 2011-12-27 2015-01-29 Ct De Inmunología Molecular Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
KR102391734B1 (ko) * 2013-03-15 2022-04-29 인3바이오 리미티드 자기조립형 합성 단백질
CU24299B1 (es) * 2013-08-02 2017-12-08 Centro De Inmunología Molecular Composiciones vacunales bivalentes basadas en los receptores de tipo 1 y 2 del factor de crecimiento epidérmico
US10105306B2 (en) * 2013-09-17 2018-10-23 Bestop Group Holdings Limited Method of preparing a growth factor concentrate
HK1194912A2 (en) * 2013-09-17 2014-10-24 Bestop Group Holdings Ltd Growth factor concentrate and the use thereof
ES2757595T3 (es) * 2014-03-11 2020-04-29 Jacques Fantini Un péptido quimérico que interactúa con los gangliósidos de la membrana celular
AU2018234783B2 (en) 2017-03-15 2024-10-24 Centro De Inmunologia Molecular Method for the treatment of patients with carcinomas
US12019073B2 (en) * 2017-03-15 2024-06-25 Centro De Inmunologia Molecular Method for the treatment of patients with carcinomas
WO2019067673A1 (en) * 2017-09-27 2019-04-04 L2 Diagnostics, Llc ERBB PEPTIDE-BASED PHARMACEUTICAL AND VACCINE COMPOSITIONS AND THEIR THERAPEUTIC USES FOR THE TREATMENT OF CANCER
CU24534B1 (es) * 2017-11-06 2021-07-02 Ct Inmunologia Molecular Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3
CU20170173A7 (es) * 2017-12-27 2019-11-04 Ct Inmunologia Molecular Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras
CN109865137A (zh) * 2019-01-23 2019-06-11 天德悦（北京）生物科技有限责任公司 经碘代乙酰基活化的琼脂糖微球在提高多肽或蛋白类免疫原免疫原性中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857637A (en) * 1986-05-07 1989-08-15 Genentech, Inc. Methods and compositions for immunologically modulating growth hormone receptor activity
IT1206250B (it) * 1987-02-18 1989-04-14 Ist Farmacoterapico It Spa Stiche umane e relativi prodotti metodo per l'estrazione di antigeni di membrana aventi proprieta' immunogene a partire da cellule neopla-
US5726292A (en) * 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
TNSN93075A1 (fr) 1992-07-08 1994-03-17 Schering Corp Utilisation de gm-csf comme adjuvant pour vaccin
EP0657471B1 (en) * 1993-12-09 2001-10-24 Centro de Inmunologia Molecular Anti ganglioside monoclonal antibodies and their use in the specific active immunotherapy of malignant tumours
CU22420A1 (es) * 1993-12-29 1996-01-31 Centro Inmunologia Molecular Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
US6149921A (en) * 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
CA2318557A1 (en) * 1998-01-16 1999-07-22 Biomira Usa Inc. Patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes

Also Published As

Publication number Publication date
ATE485833T1 (de) 2010-11-15
CN1291755C (zh) 2006-12-27
EP1356822A2 (en) 2003-10-29
HK1063726A1 (en) 2005-01-14
BRPI0116013B8 (pt) 2021-05-25
ZA200304411B (en) 2004-07-29
WO2002045746A3 (es) 2002-12-27
CN1484532A (zh) 2004-03-24
BRPI0116013B1 (pt) 2018-07-24
JP4210519B2 (ja) 2009-01-21
DE60143363D1 (de) 2010-12-09
AU2151902A (en) 2002-06-18
US20020136735A1 (en) 2002-09-26
DK1356822T3 (da) 2011-02-07
JP2004523494A (ja) 2004-08-05
EA005138B1 (ru) 2004-12-30
NZ526282A (en) 2005-01-28
KR20030061838A (ko) 2003-07-22
MXPA03005032A (es) 2004-09-10
UY27059A1 (es) 2002-04-26
EP1356822B1 (en) 2010-10-27
US7776342B2 (en) 2010-08-17
CA2431188A1 (en) 2002-06-13
KR100850473B1 (ko) 2008-08-07
EA200300640A1 (ru) 2003-12-25
BR0116013A (pt) 2004-01-06
CA2431188C (en) 2010-09-07
WO2002045746A2 (es) 2002-06-13
PE20020572A1 (es) 2002-07-31
AU2002221519B2 (en) 2006-11-23

Similar Documents

Publication Publication Date Title
UY27059A1 (es) Preparaciones para potenciar la inmunogenecidad de antígenos poco inmunogénicos
ES2445798T3 (es) Novedosos compuestos inmunoadyuvantes basados en flagelina y uso de los mismos
ES2373055T3 (es) Péptido antígeno de rechazo de cáncer derivado de glipican-3 (gpc3) para uso en pacientes positivos a la hla-a2 y producto farmacéutico que comprende el antígeno.
Abdel-Aal et al. Design of fully synthetic, self-adjuvanting vaccine incorporating the tumor-associated carbohydrate Tn antigen and lipoamino acid-based toll-like receptor 2 ligand
BRPI0518146A (pt) kit de partes, uso de um adenovìrus recombinante defectivo na replicação, e, método de vacinação de um mamìfero para a infecção por malária
EP0841941A4 (en) Novel non-pyrogenic bacterial strains and their use
ES2398492T3 (es) Proteínas de fusión que comprenden los antígenos de rechazo tumoral NY-ESO-1 y LAGE-1
WO2008057235A3 (en) Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes
BRPI0411519A (pt) membrana viral reconstituìda, método para produzir uma membrana viral reconstituìda, e, composição farmacêutica
Moyle et al. An efficient, chemically-defined semisynthetic lipid-adjuvanted nanoparticulate vaccine development system
AU2018359358B2 (en) Nano-particles that contain synthetic variants of GM3 ganglioside as adjuvants in vaccines
Apostolopoulos et al. Subunit protein-based vaccines
Warren et al. Synthetic glycopeptide-based vaccines
Palitzsch et al. Mucin glycopeptide‐protein conjugates–promising antitumor vaccine candidates
Schönbach et al. Identification of HTLV-1-specific CTL directed against synthetic and naturally processed peptides in HLA-B* 3501 transgenic mice
WO2019041056A1 (es) Vacuna recombinante contra la enteropatía proliferativa en animales
CU23009A1 (es) Preparaciones para potenciar la inmunogenicidad depreparaciones para potenciar la inmunogenicidad de antígenos poco inmunogénicos antígenos poco inmunogénicos
WO2018088509A1 (ja) マラリアワクチン
JP7045024B2 (ja) マラリアワクチン
AR042237A1 (es) Obtencion de estructuras cocleares, composiciones vacunales, adyuvantes y sus intermediarios
ES2242376T3 (es) Administracion de particulas inmunogenas mediante particulas de agshb.
CN117321069A (zh) 基于减毒呼肠孤病毒的疫苗组合物及其用途
TWI701262B (zh) 免疫原性胜肽及其用途
Sponaas et al. Immunization with gp96 from Listeria monocytogenes-infected mice is due to N-formylated listerial peptides
MY129626A (en) Preparations that potentiate immunogenicity in low immunogenic antigens

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed, e.g., due to non-payment of fee